The impact of chemoimmunotherapy on primary cold agglutinin disease and Waldenström macroglobulinemia-associated cold agglutinin syndrome. (PubMed, Front Med (Lausanne)) - Sep 19, 2026 - "When hemolysis is the dominant clinical issue and strict disease classification is difficult, fixed-duration rituximab-based CIT should be further investigated. These hypothesis-generating findings warrant validation in larger studies."
IO biomarker • Journal • Autoimmune Hemolytic Anemia • Complement-mediated Rare Disorders • Hematological Disorders • Hematological Malignancies • Infectious Disease • Lymphoma • Lymphoplasmacytic Lymphoma • Oncology • Waldenstrom Macroglobulinemia • MYD88
|
|
Kazuhiko Hirano; Kenichi Ito; Naohiro Sekiguchi; Saya Motohashi; Tomoko Kitagawa
|